EUCTR2006-001791-20-DE进行中（未招募）不适用
A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSS
niversity Hospital of Schleswig-Holstein (UKSH), Campus Lübeck0 个研究点开始时间: 2008年1月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. informed consent
- •2. documented history of Churg Strauss Syndrome:
- •a. previous or currently active vasculitis either on biopsy or based on the following surrogate parameters proposed by the EMEA group on the classification of primary systemic vasculitides for epidemiological studies [33]: dysmorphic red cells or erythrocyte casts indicative of glomerulonephritis, rapidly progressive neuropathy, alveolar hemorrhage demonstrated on bronchoalveolar lavage, episcleritis.
- •b. In agreement with recommendations of the EMEA working group on the classification of primary systemic vasculitides for epidemiological studies the criteria of the American College of Rheumatology are used for classification of Churg Strauss Syndrome, as in contrast to other criteria (Lanham, CHCC) the ACR criteria are data-driven and not based on expert opinion alone. Four or more of the seven (ACR) for classification of Churg-Strauss syndrome need to be fulfilled (see [34] for definitions) in order to yield a sensitivity of 85% and specificity of 99.7 %:
- •ii. Eosinophilia > 10 % on peripheral blood white cell count
- •iii. History of allergy
- •iv. Mononeuropathy or Polyneuropathy
- •v. Pulmonary infiltrates, non-fixed
- •vi. Paranasal sinus abnormality
- •vii. Extravascular eosinophils on tissue biopsy
- •3. active disease defined as either
- •a. active vasculitis (BVAS > 3) and/or
- •b. symptomatic tissue eosinophilia and
- •c. a prednisolone demand of >- 12.5 mg/day to control disease
- •4. Subjects must complete screening and baseline assessment as outlined below
- •5. stable corticosteroid dose of > 12.5 mg prednisolone for at least one week
- •6. treatment with cyclophosphamide (pulse or daily oral) or methotrexate in a stable dose for at least 4 weeks
- •7. Male or female, 18-80 years of age. A female patient may be included only if
- •i. She is not pregnant or nursing
- •ii. Of non-childbearing potential
- •iii. Are of child-bearing potential but have a negative pregnancy test and agree to practice birth control
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Life threatening disease or other critical illness deemed inappropriate for inclusion in the study by the principal investigator. Among others, the following manifestations of CSS are considered potentially life-threatening:
- •a. severe alveolar hemorrhage requiring blood transfusions or mechanical respiratory support
- •b. rapid progressive glomerulonephritis requiring dialysis
- •c. severe gastrointestinal involvement (i.e. gangrene, GI-bleeding requiring transfusions)
- •d. severe CNS involvement (i.e. ischemic stroke)
- •e. severe cardiac involvement (i.e. life-threatening arrhythmias or cardiac failure as outlined below)
- •2. Treatment with other immunosuppressive agents within 4 weeks prior to randomisation. Leflunomide must have been washed out according to current guidelines (cholestyramine for 11 days) before entry of the study. MTX or CYC are allowed if their dosage has not been changed within the last 4 weeks.
- •3. Corticosteroid pulse of > 60 mg within the last three weeks prior to randomisation.
- •4. known secondary cause of eosinophilia: drug eruption, parasitic infection, HIV infection, history of graft versus host disease, acute/chronic eosinophilic leukemia,
- •5. no history or clinical features of vasculitis, suggesting a diagnosis of hypereosinophilic syndrome rather than Churg Strauss Syndrome
- •6. Diagnosis of other primary systemic vasculitis: Wegener’s granulomatosis, microscopic polyangiitis etc.
- •7. currently active malignant disease
- •8. abnormal laboratory values:
- •a. serum creatinine >- 3 times institutional upper normal limit (UNL)
- •b. AST or ALT > UNL
- •c. Platelet count < 50.000/µL
- •9. Impaired cardiac function defined as:
- •a. Left ventricular ejection fraction < 20 %
- •b. NYHA class IIIb or IV
- •c. Myocardial infarction
- •10. history of allergic reaction due to monoclonal antibodies
- •11. prior treatment with anti-hIL-5 monoclonal antibody
- •12. exposure to investigational drug within 30 days prior to randomisation
- •13. positive pregnancy test
研究者
相似试验
进行中（未招募）
1 期
A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease.EUCTR2015-002571-24-GBJoint Research Office24
已完成
2 期
A clinical study to evaluate safety andEffectiveness of the Elure advanced skin whitening products (Advanced whitening lotion andAdvanced whitening night cream) in imparting skin fairness on healthy human volunteers.CTRI/2012/01/002363Syneron P Ltd40
已完成
1 期
Phase 1 study to evaluate the pharmacokinetics, safety, tolerability, and taste of tecovirimat pediatric formulationsISRCTN13846827Siga Technologies (United States)12
撤回
不适用
An open label, single arm, multicenter phase II study of AST-301 in patients with advanced or metastatic salivary gland tumor with HER2 overexpressioKCT0007106Seoul National University Hospital36
招募中
Unknown
An open label, single arm, multicenter phase II study of zanidatamab in patients with HER2 positive salivary gland carcinomaKCT0008350Seoul National University Hospital32